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Bladder cancer
In Western society cancer remains second to
cardiovascular disease as the most common
cause of death. Bladder cancer is the seventh
most common malignancy worldwide. Every
year in the United Kingdom, about 10,100
people are diagnosed with bladder cancer and
around 4,700 die from it (Cancer Research
UK). It is a potentially curable disease with up
to 80% of cases being superficial and
amenable to surgical resection [1]. However,
bladder cancer is one of the most prevalent
malignancies, mostly because it has the
highest rate of recurrence among all cancer
types. Up to 80% of treated superficial bladder
cancers recur. The propensity to recur and the
possibility of disease progression require
aggressive surveillance. This ranks bladder
cancer as one of the most expensive
malignancies to treat. The necessity of
repeated screening for recurrence indicates the
urgent need for novel biological or molecular
markers as alternatives to invasive standard
procedures.
Haemostasis and cancer
Since Armand Trousseau (1865) [2] reported
the frequent occurrence of venous thrombosis
in patients with gastric carcinoma, a
considerable clinical, laboratory and
pharmacological body of evidence, both
human and experimental, have emerged to
suggest that haemostasis is frequently activated
in malignancy [3–6] and that interfering with
the haemostatic mechanisms may compromise
tumour growth and consequently improve the
effectiveness of the current treatment (surgery,
radiotherapy, and chemotherapy). Clinical
manifestation of the haemostatic disorders may
vary according to tumour type, but generally
thromboembolic disorders are more frequent in
patients with solid tumours. Production of
procoagulant activity by endothelial cells,
blood monocytes, tumour-associated
macrophages, tumour cells and stroma may be
increased in patients with cancer. Malignant
tissue and cultured tumour cells may express
cancer procoagulant (an apparently cancer-
specific procoagulant that can directly generate
thrombin through the activation of factor X) [7]
and/or tissue factor (TF) [8] which facilitate
fibrin deposition and aid tumour growth and
metastasis [9]. The mechanisms of TF
activation in a tumour-bearing organism are
outlined in Figure 1. The role of TF in tumour
neovascularisation and angiogenesis has been
the subject of increased interest [10–12]. Tissue
factor is also involved in a variety of other
biological processes, independent of its role as
the primary physiological initiator of blood
coagulation activation. These include blood
vessel development, intra-cellular signalling,
cell migration, cell adhesion and inflammation
[13-15]. 
Tissue factor
Tissue factor is a single chain transmembrane
glycoprotein with no intrinsic protease activity
(Figure 2). It serves as a cellular receptor and
essential cofactor for the blood coagulation
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Figure 1 (left): Potential mechanisms mediating tissue factor (TF) expression in patients with cancer. Macrophages and peripheral blood monocytes can be stimulat-
ed by tumour cells or their related products to produce TF, which activates the clotting cascade. Tumour cells may themselves produce TF or synthesise cancer pro-
coagulant (CP), which directly activates FX. Prothrombin generation may be facilitated by shed tumour-membrane vesicles. Thrombin then cleaves fibrinogen
derived from plasma under the influence of the vascular permeability factor (VPF). Fibrin is deposited around the tumour, liberated fibrinopeptide A (FpA) leaks
back into the circulating blood (adapted from ref 37).
Figure 2 (right): A model of tissue factor. This diagram shows the extracellular, transmembrane, and intracellular domains of tissue factor.
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factor VII and factor VIIa in the activation of factor X and
factor IX, respectively [16]. After injury or damage to the
vascular wall, TF is exposed to blood and binds plasma factor
VII (TF:Factor VII), which, upon binding TF, attains greatly
increased activity. No proteolytic modifications are involved in
the association between TF and factor VII. Factor VII is then
auto-cleaved within the complex to activated factor VII (Factor
VIIa). The TF:Factor VII/Factor VIIa complex then directly
catalyses the conversion of factor IX to factor IXa and factor X
to factor Xa. The transformation of factor X to factor Xa in the
presence of factor Va, Ca2+ and phospholipids forms what is
commonly known as ‘the prothrombinase complex’ which
then converts prothrombin (Factor II) to thrombin (Factor IIa),
resulting ultimately in platelet activation and fibrin formation
(Figure 3). The thrombin generation triggers both pro-
coagulant and anticoagulant pathways.
Urinary tissue factor
Normal and malignant bladder tissue both express TF [17].
Nonetheless, TF is over-expressed in malignant tissues and its
expression has recently been shown to be an independent
predictor of disease-specific survival in N0-classified muscle-
invasive transitional cell carcinoma of the bladder, treated by
radical cystectomy [18]. It has also been suggested that studying
TF-expression in such patients may help identify those who are
at higher risk of disease progression [18]. Tissue factor is found
in various biological fluids where it is easily accessible and its
levels correlate with different pathologies. Its use as a diagnostic
and/or prognostic indicator in various disease conditions,
particular those that are associated with a hypercoagulable state
or inflammatory reactions, has been proposed by various
investigators. For instance, elevated levels of TF were found in
plasma and serum samples obtained from individuals with
different types of solid tumours [19-21]. Patients with bladder
cancer showed significantly higher plasma TF levels compared
with healthy volunteers [22]. The evaluation of urinary
parameters as a cancer marker has long been seen as attractive
[23,24]. Urine is known to possess a powerful procoagulant
activity that appears to facilitate haemostasis in the urinary tract
[25]. This urinary procoagulant was found to be TF [26]. It is
not likely that uTF is derived from the blood, since it is
associated with lipid-particles that are too large to pass through
the glomerular basement membrane unless glomeruli are
damaged. Thus, uTF is produced by the kidney, and is probably
of tubular origin. Positive signals for TF antigen were found in
both distal and proximal tubules but not glomeruli [27]. We
believe that, in patients with cancer or inflammatory disease,
bioactive stimulants released from malignant or inflammatory
cells into the vascular compartment are excreted via the kidney,
concentrating in urine to stimulate, in transit, tubular
epithelium to release TF [28]. Indeed, uTF measurements are
not significantly affected by glomerular permeability and
filtration, tubular function or by the presence of urinary
contaminants [29]. Urinary TF levels are elevated in patients
with colorectal cancer, inflammatory bowel disease and breast
cancer. Although patients with benign colorectal and breast
disease also had increased levels compared to normal controls
or patients with rheumatoid arthritis, these were less than those
in the malignant group [26,30]. Subsequently, Adamson et al
showed increased levels of uTF in patients with transitional cell
carcinoma of the bladder and prostate cancer compared with
controls and patients with benign prostatic hypertrophy [31,32].
Recently, using a highly reproducible one-stage kinetic
Figure 3 (left): Cellular tissue-factor–initiated coagulation. Factor (F) VII binds tissue factor (TF) on TF-bearing cells and is auto-activated to FVIIa. A trace
amount of FVIIa is also found in the circulation. The resulting complex (TF:FVIIa) activates FX and FIX. The activated FX generates a small amount of thrombin
(IIa). In an FXa dependent feedback system, TF-pathway inhibitor (TFPI) quickly binds and inhibits the TF:FVIIa complex. However, the little FIIa burst activates
platelets and FV, releases and activates FVIII from von Willebrand (vWF), and activates FXI. Activated FIX binds to the activated platelets and activates FX.
Platelet-generated FXa then generates large amounts of FIIa, which is needed to form the fibrin clot (adapted from ref 37).
Figure 4 (right): Urinary tissue factor levels in controls and patients with bladder cancer. The distribution of urinary tissue factor level (ng/ml) in normal controls,
renal stone, non-inflammatory (negative cystoscopy following haematuria) and inflammatory benign disease (cystitis) and malignant disease of the bladder. Boxes
show median and interquartile ranges. Red circles represent benign inflammatory disease.
Figure 5: Urinary tissue factor and malignant bladder recurrence. The distribu-
tion of urinary tissue factor level (ng/ml) in patients with and without malig-
nant bladder recurrence. Results are shown with superimposed medians and
interquartile ranges.
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chromogenic assay, we showed a significant increase in uTF
levels in patients with malignant disease of the bladder
compared with normal controls or subjects with benign non-
inflammatory disease (Figure 4). Urinary TF levels also showed
a positive and significant correlation with markers of disease
progression, metastasis (e.g., bone scan status) and malignant
recurrence, Figure 5 [33].
Urinary tissue factor in patients with advanced bladder
cancer
Interestingly, patients with advanced bladder cancer showed a
marked increase in their uTF values of between 70 and 115
ng/ml (normal levels are around 27 ng/ml) [33]. The normal
source of uTF is assumed to be the kidney [27,28], but several
other possible sources could be considered, especially in
patients with bladder cancer:
1. Exfoliated tumour cells. In our laboratory TF localised to a
bladder cancer cell line (MGH-u 1) as assessed by
Transmission Electron Microscopy and Confocal Microscopy.
In addition, the activity of both exfoliated tumour cells and
MGH-u 1 cells was significantly inhibited by murine
monoclonal antibody to human TF.
2. Residual tumour still resident in the bladder wall may release
TF, especially in patients with muscle invasive disease.
3. Charge-related changes in the plasma membrane, to which
tumour cells are susceptible can affect TF expression or de-
encryption and consequently enhance TF functional activity
[34]. Multi-drug resistance (MDR) is a common
phenomenon in bladder cancer [9]. Classical MDR causes
membrane charge alterations comparable to those occurring
when monocytes are stimulated to produce TF as detected
by binding of Annexin V and MGH-u1. MDR clones resistant
to both adriamycin and mitomycin-c are reported to express
6-fold more immunological and functional TF than their
parental line under the same culture conditions [11].
4. Cell lysis as a result of exposure to urine may also enhance
the amount of the released TF by cancer cells. Therefore, the
total amount of the detectable TF will be higher in the urine
of some patients with advanced bladder cancer. This
suggests that TF may reflect a feature of the biology of
advanced bladder tumours, with levels related to disease
stages. Tissue factor is also linked to angiogenesis, cell
mugration, cell adhesion and intra-cellular signaling and this
may have a bearing on its role in the natural history of
bladder cancer. The mechanistic basis for TF induction and
its diagnostic and/or prognostic value value as a marker for
bladder cancer may warrant further investigation.
Conclusion
Increased uTF levels in patients with advanced bladder cancer
provide further evidence of abnormal haemostasis in
malignancy and suggest that the determination of uTF may
provide a useful screening and/or prognostic test in patients
with bladder cancer, particularly if the similar and
confounding influence of inflammation on secreted TF can be
overcome. n
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